AbbVie (NYSE: ABBV) announced the following on Friday:In consultation with the U.S. Food and Drug Administration (FDA), the U.S. Product ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE